within Pharmacolibrary.Drugs.R_RespiratorySystem.R07A_OtherRespiratorySystemProducts.R07AX30_IvacaftorAndLumacaftor;

model IvacaftorAndLumacaftor
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.35,
    Cl = 4.805555555555555e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0947,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 60);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>IvacaftorAndLumacaftor</td></tr><tr><td>ATC code:</td><td>R07AX30</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>94.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>17.3</td><td>L/h (ivacaftor), 2.54 L/h (lumacaftor)</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ivacaftor and lumacaftor is a fixed-dose combination medication used to treat cystic fibrosis in patients with homozygous F508del mutation in the CFTR gene. Ivacaftor acts as a CFTR potentiator, while lumacaftor functions as a CFTR corrector. The combination is approved for use and marketed under the trade name Orkambi.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with cystic fibrosis, after repeated oral dosing of lumacaftor/ivacaftor combination (400 mg/250 mg) every 12 hours under fed conditions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R07AX30 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end IvacaftorAndLumacaftor;
